The first baby has been born after using California-based Lady Technologies’ Kegg clinically proven fertility tracker.

The device senses cervical fluid and also doubles as a kegel ball.

The first confirmed baby conceived using the FDA-registered device is Isaiah, born in Omaha, Nebraska in March to parents Andrea (32) and Matthew (33). In 2020, 27% of respondents to a Kegg survey distributed to users noted that they had successfully conceived.

Some 58% of Kegg users who are trying to conceive are seeking their first baby while the other half trying to conceive already have at least one child. Andrea, who was already a mother to one child, had been trying to conceive for a few months before discovering Kegg. She was one of the first Indiegogo backers of the product and she conceived after her first cycle using Kegg.

“I suffer from multiple health conditions which make trying to conceive very challenging,” said Andrea. “I was searching for a fertility tracker that would help me know my full fertile window in advance in order to be able to time intercourse properly. I thought temping was too limiting as it didn’t alert me to when my fertile window started. I wanted something that took the guesswork out of this for me, in a very convenient way, and that’s when I found Kegg. My husband travels for work, making timing even more crucial. I wouldn’t have known I was in my fertile window without Kegg.”

Kegg senses the electrolytes in cervical mucus to help predict the fertile window and it doubles as a kegel ball for pelvic floor exercises. When it comes to cervical fluid, no other biological marker has been proven to give such dependable, real-time insights for women trying to conceive, claims the company. This makes cervical fluid the key fertility sign to recognising the fertile window and possible ovulation within each menstrual cycle.

With fertile cervical mucus, sperm can survive for up to five days within the reproductive tract. The fertile window prediction is a five-day window marked in green on the app, placed at the beginning of the user’s cycle, during which time Kegg predicts the greatest likelihood of conception for the entire cycle.

Proprietary impedance technology tracks the changes of electrolyte levels in cervical fluids associated with the beginning and end of the fertile window.

Through patent-pending sensing technology, it can help predict a more accurate and personalised fertile window compared with probability-based products that estimate the fertile window, therefore making them rarely accurate for irregular cycles.

Unlike other fertility products that must be worn through the night, using Kegg only takes two minutes daily. It also has the kegel exercise device to support pelvic floor health and can increase lubrication and circulation for better data collection.

“Our first customers started their tracking journey with Kegg in June,” said Lady Technologies CEO Kristina Cahojova. “We were elated to have heard from several Keggsters who have successfully conceived and we are grateful for the resilience of those women who are still trying. We’re looking forward to welcoming more Kegg babies this summer, and in fact have personally heard from 14 women that they will be moms in the next few months thanks to Kegg.”

Launched in the USA in summer 2020 and in Singapore in October 2020, Kegg sold out its first batch within months.

Lady Technologies was launched in 2020 by Cahojova and her team. Kegg is an FDA-registered two-in-one medical device that combines fertility tracking with pelvic floor exercising. Following a successful beta launch and Indiegogo campaign that reached its goal in just 36 hours, Lady Technologies successfully closed a seed round and is now actively raising a series A. Investors include Crescent Ridge Partners, SOSV, Texas Halo Fund, Fermata Fund, MegaForce and several angel investors.